Skip to main content

Catalyst Calendar

Scope

Tue, Sep 8, 2026

1 updates
BLTE
6:00 AM

Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1

U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, 2027 If approved, tinlarebant would be the first-ever approved treatment for

belitebio.com

Tue, Sep 1, 2026

1 updates
BLTE
8:00 AM

Belite Bio to Participate in Four Upcoming Investor Conferences

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that

belitebio.com

Mon, Aug 24, 2026

1 updates
BLTE
4:00 PM

Belite Bio to Host Virtual Commercial Day on September 2, 2026

SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it

belitebio.com

Fri, Aug 21, 2026

1 updates
BLTE
8:00 AM

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

SAN DIEGO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that

Presentation / Abstract • Phase 3SOG oral presentation Thu, Aug 27, 2026, 8:30 PM CESTbelitebio.com

Wed, Aug 12, 2026

1 updates
BLTE
9:46 PM

Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update

U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) with Priority Review for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); Prescription Drug User Fee Act (PDUFA) target action date of February 12, 2027 Company presented additional positive secondary

Presentation / Abstract • Phase 3ASRS oral presentation Thu, Aug 13, 2026, 4:30 PM ETbelitebio.com

Tue, Aug 11, 2026

1 updates

Thu, Aug 6, 2026

1 updates

Mon, Jul 20, 2026

1 updates
BLTE
8:00 AM

Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1

Tinlarebant is the first therapeutic candidate to demonstrate clinical efficacy in Stargardt disease type 1, having met the primary efficacy endpoint, reduction in lesion growth Presentation to include positive update on secondary endpoints, with quantitative autofluorescence showing a marked

Presentation / Abstract • Phase 3ASRS oral presentation Sat, Jul 18, 2026belitebio.com

Wed, Jul 15, 2026

1 updates

Mon, Jul 6, 2026

2 updates
BLTE
7:00 AM

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio ® ” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that

Presentation / Abstract • Phase 3ISCEV oral presentation Wed, Jul 8, 2026, 12:00 PM AESTbelitebio.com